Studies how CD9 gene regulation relates to relapse in childhood leukemia
Samples bone marrow and blood from children newly diagnosed with B-cell acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
Key facts
- Where
- Angers, Brest, and Rennes, FranceSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 17 years old?
Source: NCT06649253, who can take part
Where in France
- CHU AngersAngers, FranceTaking people
- Chu BrestBrest, FranceTaking people
- CHU RennesRennes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rennes University Hospital
- Trial code
- NCT06649253
- Record updated
- 2 January 2026
- Original description
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.Read full original descriptionShow less
REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Inclusion: Under 18 years; With established diagnosis of B-ALL; Initial diagnosis made in the investigating centre; Having received oral and written information about the protocol, or oral only if the patient is unable to read; Having signed a consent form if the patient is capable of giving informed written consent; Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent; Beneficiary of a social security scheme.
Exclusion: Patient of childbearing age without effective contraception; Isolated extramedullary involvement at inclusion; Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.